SWK — Investor Presentation (November 2024)
28 slides from SWK's investor presentation, Nov 15, 2024
Slide 1: Collaborative Approach to Life Science Financing Shareholder Presentation
1 Collaborative Approach to Life Science Financing Shareholder Presentation November 2024
Slide 2: Forward-looking and Cautionary Statements
2 Forward - looking and Cautionary Statements Statements in this presentation that are not strictly historical, and any statements regarding events or developments that we be lieve or anticipate will or may occur in the future are "forward - looking" statements within the meaning of the federal secu
Slide 3: SWK Holdings - Overview
SWK Holdings - Overview 3 Underserved, High - Need Market Demonstrated Success, Attractive Returns Focus on Shareholder Returns Custom financing solutions for commercial - stage healthcare companies and royalty owners • SWK targets $5M to $25M financings, a market niche that is less competitive and
Slide 4: Operating Segments
4 Operating Segments LIFE SCIENCE SPECIALTY FINANCE ENTERIS BIOPHARMA • Senior secured term loans • Royalties • Synthetic royalties • Hybrid structures • CDMO and CMO services • Peptelligence ® dosing technologies • 505b2 drug outlicensing SWK operates through two segments: Life Science Specialty Fi
Slide 5: Why Life Science Finance?
5 Why Life Science Finance? Tap into underlying demand that is pervasive, growing, and minimally correlated with economic cycles • Healthcare spend is large and increasing, representing 20% of U.S. GDP; forecast to grow at a 5% CAGR through 2030 1 • Sector has demonstrated durability as S&P 500 sale
Slide 6: Value Creation Strategy
6 Value Creation Strategy SWK believes this strategy will continue to achieve a 10%+ book value per share CAGR Deploy balance sheet capital into secured financing portfolio • SWK has established reputation as a go - to capital provider in our market segment • Majority of financings structured with w
Slide 7: Book Value Components
7 Book Value Components Tangible Finance Book Value / Share = $20.42 • Excludes value of deferred tax asset and Enteris PP&E • SWK’s targets 10%+ CAGR of tangible finance book value / share Plus: Enteris Biopharma Net Book Value / Share = $0.40 • Strategic partner has option to purchase certain prop
Slide 8: Corporate Milestones
8 Corporate Milestones 2016 x Team rebuilt and investment process improved x Focus on 1LTLs and Royalties only (no 2Ls, equity, high yield) x Ended year with $130.0M investment assets 2018 x Secured $20M credit facility with Cadence Bank (f/k/a State Bank) x Announced share repurchase program in 4Q1
Slide 9: Third Quarter 2024 Recap
Third Quarter 2024 Recap 9 CONFIDENTIAL CORPORATE UPDATES FINANCE RECEIVABLES UPDATES • During the third quarter of 2024, SWK repurchased ~190K shares of stock for a total cost of ~$3.2M • Year - to - date 2024 through November 11, SWK has repurchased ~345K shares of stock for a total cost of ~$5.9M
Slide 10: Finance Segment Portfolio Overview
10 Finance Segment Portfolio Overview: 2Q24 1) Includes public company warrants and shares; private warrants carried at zero value 2) As of November 2024 • Gross Finance Receivables: $270.2M • Gross Total Investment Assets: $273.0M 1 • Allowance for Loan Loss: $14.3M Financing Segment Portfolio Valu
Slide 11: Financial Snapshot
$212.5 $189.7 $237.9 $290.2 $273.0 2020 2021 2022 2023 3Q24 Total Investments Assets ($ in millions; at end of period; gross of/before CECL) $36.7 $56.2 $41.5 $37.8 $42.5 2020 2021 2022 2023 TTM 3Q24 Total Revenue ($ in millions) $21.1 $35.7 $18.1 $18.4 $13.6 2020 2021 2022 2023 TTM 3Q24 Non - GAAP
Slide 12: Attractive Portfolio Yields
12 Attractive Portfolio Yields SWK Targets Low - to - Mid Teens Effective Yields 1 3Q24 Finance Segment Effective Yield was 14.6% 1) Effective yield is the rate at which income is expected to be recognized pursuant to the Company’s revenue recognition polici es, if all payments are received pursuant
Slide 13: Attractive Portfolio Yields: Realized vs. Effective Yield
13.8% 13.9% 13.8% 13.8% 13.9% 14.2% 14.3% 13.9% 15.5% 14.5% 14.0% 14.4% 14.2% 14.6% 14.6% 16.8% 22.8% 18.8% 20.1% 22.5% 15.0% 17.5% 11.0% 15.3% 15.4% 14.7% 14.1% 15.2% 15.4% 13.8% 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 Realized Yield vs. Effective Yield 1 (at end
Slide 14: Current Structured Credit Portfolio
Current Structured Credit Portfolio MolecuLight 01.04.2022 $10.0 million Structured Credit Trio Healthcare 07.01.2021 $9.5 million Structured Credit Biotricity 12.27.2021 $12.0 million Structured Credit NeoLight 02.17.2023 $5.0 million Structured Credit 14 4WEB Medical 07.01.2021 $20.0 million Struc
Slide 15: Current Royalty Portfolio
15 Current Royalty Portfolio Relief Therapeutics 08.02.2024 $11.0 million Royalty Portfolio Acquisition Iluvien 12.18.2020 $16.5 million Royalty Acquisition ForFivo (IntelGenx) 08.05.2016 $6.0 million Royalty Acquisition Ideal Implant 04.27.2021 $5.0 million Reorg Synthetic Royalty Financing Best AB
Slide 16: Portfolio Realizations Exit History
16 Portfolio Realizations Exit History ~12 Yrs. Exited Deals 33 Exits Cash Deployed ~$370M Cash Returned ~$530M MOIC 1.4x IRR 17.3% Figures reflective of SWKH balance sheet (i . e . , excludes managed/partner transactions) ($s in Ms) Date Cash Investments # Security Invested Paid Off Invested Receiv
Slide 17: Portfolio Realizations to Strategic Buyers
17 Portfolio Realizations to Strategic Buyers 13 realizations to strategic buyers demonstrated a median 28% LTV of SWK’s original loan value 9 of the 13 businesses were not profitable at time of sale, validating SWK’s revenue and IP - based underwriting methodology 1) Attachment point measured as fa
Slide 18: SWK Sourcing
18 SWK Sourcing • Cultivates and maintains a diverse array of longstanding, proprietary deal sources • Consistently sources over 100 actionable investment opportunities per year • Maintains disciplined “look - to - book” ratio of approximately 5% 5 - Year Avg. (2019 – 2023 CYs) $ Opp. (Ms) % of Deal
Slide 19: Financing Structures
Financing Structures 19 Product Acquisition • Primarily first lien, senior secured, floating rate loans • Typically include covenants, prepayment penalties, origination and exit fees, and warrant coverage • Provide working capital to support product commercialization and M&A Hybrid Financing Synthet
Slide 20: Historical Financing: Narcan Royalty
Historical Financing: Narcan Royalty 20 OPPORTUNITY SOLUTION • Opiant is a publicly - traded drug development company that receives a royalty on Narcan for developing the drug’s unique formulation – Novel formulation has a faster time to onset and more convenient and safer administration • Opiant ne
Slide 21: Historical Financing: Galil Medical
Historical Financing: Galil Medical 21 OPPORTUNITY SOLUTION • In 2014, Galil was on the cusp of accelerating revenue growth, but was not yet cash - flow positive and could not tap traditional financing channels • Galil needed additional capital to run clinical trials and expand its sales force • In
Slide 22: Enteris Corporate Overview
22 Enteris Corporate Overview CDMO Platform Revenue - generating CDMO platform Drug Delivery Technology Internal 505(b)(2) Pipeline Strategic Partnership • Peptelligence platform allows oral delivery of drugs that are typically injected, including peptides and BCS class II, III, and IV small molecul
Slide 23: Leadership Team
23 Leadership Team Jody Staggs President and CEO • Joined in 2015 • Co - founded PBS Capital Management, predecessor to SWK • Prior to PBS, served as Senior Portfolio Analyst at Highland Capital Management • Investing experience in multiple asset classes Dr. Paul Shields Enteris subsidiary CEO • Joi
Slide 24: Why Invest in SWKH – Attractive Risk Reward Scenario
Why Invest in SWKH – Attractive Risk Reward Scenario 24 Minimally Levered Balance Sheet and Buyback • SWK story is not widely known, having uplisted to Nasdaq without benefit of traditional IPO • Analyst coverage and proactive investor relations effort have helped to increase SWK’s visibility • With
Slide 25: Reconciliation of Non-GAAP Adjusted Net Income
25 Reconciliation of Non - GAAP Adjusted Net Income The following table provides a reconciliation of SWK's reported (GAAP) consolidated net income to SWK's adjusted consolidated ne t income (Non - GAAP) for the periods denoted in the table. The table eliminates provisions for income taxes, non - cas
Slide 26: Reconciliation of Non-GAAP Specialty Finance Net Income
26 Reconciliation of Non - GAAP Specialty Finance Net Income The following table provides a reconciliation of SWK's consolidated adjusted income before provision for income taxes, listed in the table above, to the non - GAAP adjusted net income for the specialty finance business for the periods deno
Slide 27: Contact Information
27 Contact Information CONFIDENTIAL SWK Senior Management Investor & Media Relations: IR Labs • Jody Staggs: ̶ Phone: 972.687.7252 ̶ Email: jstaggs@swkhold.com • Office address: 5956 Sherry Lane, Unit 650 Dallas, TX 75225 • Website: www.swkhold.com • Ira Gostin: ̶ Phone: 775.391.0213 ̶ Email: ira@ir
Slide 28: Collaborative Approach to Life Science Financing
28 Collaborative Approach to Life Science Financing